Arribas JR, Bhagani S, Lobo SM, Khaertynova I, Mateu L, Fishchuk R, et al. Randomized trial of Molnupiravir or placebo in patients hospitalized with Covid-19. NEJM Evid. 2022;1(2):EVIDoa2100044.

Article  PubMed  Google Scholar 

FDA US. Bioavailability and Bioequivalence Studies Submitted in NDAs or INDs — General Considerations https://www.fda.gov/media/88254/download . 2014.

Fiore JL, Jin Y, Heimbach T, Patel SR, Zhao T, Matthews CZ, et al. Pharmacokinetics and bioequivalence of a molnupiravir tablet formulation compared with the molnupiravir capsule formulation in healthy adult participants-a randomized, open-label, three-period, crossover study. Antimicrob Agents Chemother. 2025;69(3):e0143424.

Article  PubMed  PubMed Central  Google Scholar 

Mackie C, Arora S, Seo P, Moody R, Rege B, Pepin X, Heimbach T, Tannergren C, Mitra A, Suarez-Sharp S, Borges LN, Kijima S, Kotzagiorgis E, Malamatari M, Veerasingham S, Polli JE, Rullo G. Physiologically Based Biopharmaceutics Modeling (PBBM): Best Practices for Drug Product Quality, Regulatory and Industry Perspectives: 2023 Workshop Summary Report. Molecular Pharmaceutics. 2024.

Arora S, Pepin X, Jamei M, Sharma P, Heimbach T, Wagner C, et al. Development of a Physiologically Based Biopharmaceutics Model Report Template: Considerations for Improved Quality in View of Regulatory Submissions. Mol Pharm. 2025;22(6):2735–46.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Heimbach T, Musuamba Tshinanu F, Raines K, Borges L, Kijima S, Malamatari M, et al. PBBM Considerations for Base Models, Model Validation, and Application Steps: Workshop Summary Report. Mol Pharm. 2024;21(11):5353–72.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Pepin X, Arora S, Borges L, Cano-Vega M, Carducci T, Chatterjee P, et al. Parameterization of Physiologically Based Biopharmaceutics Models: Workshop Summary Report. Mol Pharm. 2024;21(8):3697–731.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Tannergren C, Arora S, Babiskin A, Borges L, Chatterjee P, Cheng Y-H, et al. Current State and New Horizons in Applications of Physiologically Based Biopharmaceutics Modeling (PBBM): A Workshop Report. Mol Pharm. 2025;22(1):5–27.

Article  CAS  PubMed  Google Scholar 

Heimbach T, Kesisoglou F, Novakovic J, Tistaert C, Mueller-Zsigmondy M, Kollipara S, et al. Establishing the Bioequivalence Safe Space for Immediate-Release Oral Dosage Forms using Physiologically Based Biopharmaceutics Modeling (PBBM): Case Studies. J Pharm Sci. 2021;110(12):3896–906.

Article  CAS  PubMed  Google Scholar 

Hermans A, Abend AM, Kesisoglou F, Flanagan T, Cohen MJ, Diaz DA, et al. Approaches for Establishing Clinically Relevant Dissolution Specifications for Immediate Release Solid Oral Dosage Forms. AAPS J. 2017;19(6):1537–49.

Article  CAS  PubMed  Google Scholar 

Wu F, Shah H, Li M, Duan P, Zhao P, Suarez S, et al. Biopharmaceutics applications of physiologically based pharmacokinetic absorption modeling and simulation in regulatory submissions to the US Food and Drug Administration for new drugs. AAPS J. 2021;23(2):1–14.

Article  Google Scholar 

Wang M, Heimbach T, Zhu W, Wu D, Reuter KG, Kesisoglou F. Physiologically Based Biopharmaceutics Modeling for Gefapixant IR Formulation Development and Defining the Bioequivalence Dissolution Safe Space. AAPS J. 2024;26(4):69.

Article  PubMed  Google Scholar 

FDA US. The Use of Physiologically Based Pharmacokinetic Analyses — Biopharmaceutics Applications for Oral Drug Product Development, Manufacturing Changes, and Controls https://www.fda.gov/media/142500/download . 2020.

Pepin XJH, Flanagan TR, Holt DJ, Eidelman A, Treacy D, Rowlings CE. Justification of Drug Product Dissolution Rate and Drug Substance Particle Size Specifications Based on Absorption PBPK Modeling for Lesinurad Immediate Release Tablets. Mol Pharm. 2016;13(9):3256–69.

Article  CAS  PubMed  Google Scholar 

Painter WP, Holman W, Bush JA, Almazedi F, Malik H, Eraut N, Morin MJ, Szewczyk LJ, Painter GR. Human Safety, Tolerability, and Pharmacokinetics of Molnupiravir, a Novel Broad-Spectrum Oral Antiviral Agent with Activity Against SARS-CoV-2. Antimicrob Agents Chemother. 2021;65(5).

Amidon GL, Lennernäs H, Shah VP, Crison JR. A theoretical basis for a biopharmaceutic drug classification: the correlation of in vitro drug product dissolution and in vivo bioavailability. Pharm Res. 1995;12(3):413–20.

Article  CAS  PubMed  Google Scholar 

Heimbach T, Wu D. (T0930–07–38) Dissolution Bioequivalence Safe Space Assessment of Molnupiravir and NHC Using Physiologically Based Biopharmaceutics Modeling. 2026 March 2nd. Available from: https://www.eventscribe.net/2022/PharmSci360/fsPopup.asp?PosterID=501417&mode=posterinfo .

Lennernäs H. Regional intestinal drug permeation: biopharmaceutics and drug development. Eur J Pharm Sci. 2014;57:333–41.

Article  PubMed  Google Scholar 

Bade R, Bothe JR, Sirota E, Brunskill APJ, Newman JA, Zhang Y, et al. Polymorphs, particle size, and a pandemic: development of a scalable crystallization process for molnupiravir, an antiviral for the treatment of COVID-19. Org Process Res Dev. 2023;27(11):2100–10.

Article  CAS  Google Scholar 

FDA US. Dissolution Testing and Acceptance Criteria for Immediate-Release Solid Oral Dosage Form Drug Products Containing High Solubility Drug Substances Guidance for Industry. 2026 April 1st, 2026. Available from: https://www.fda.gov/files/drugs/published/Dissolution-Testing-and-Acceptance-Criteria-for-Immediate-Release-Solid-Oral-Dosage-Form-Drug-Products-Containing-High-Solubility-Drug-Substances-Guidance-for-Industry.pdf .

Heimbach T, Suarez-Sharp S, Kakhi M, Holmstock N, Olivares-Morales A, Pepin X, et al. Dissolution and translational modeling strategies toward establishing an in vitro-in vivo link—a workshop summary report. In.: Springer; 2019.

Book  Google Scholar 

Sutton SC, Nause R, Gandelman K. The impact of gastric pH, volume, and emptying on the food effect of ziprasidone oral absorption. AAPS J. 2017;19(4):1084–90.

Article  CAS  PubMed  Google Scholar 

Hosea NA, Collard WT, Cole S, Maurer TS, Fang RX, Jones H, et al. Prediction of human pharmacokinetics from preclinical information: comparative accuracy of quantitative prediction approaches. J Clin Pharmacol. 2009;49(5):513–33.

Article  CAS  PubMed  Google Scholar 

Takano R, Furumoto K, Shiraki K, Takata N, Hayashi Y, Aso Y, et al. Rate-limit

Article  CAS  PubMed  Google Scholar